149 related articles for article (PubMed ID: 37755520)
1. The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS ≥ 3 lesions.
Zattoni F; Pereira LJP; Marra G; Valerio M; Olivier J; Puche-Sanz I; Rajwa P; Maggi M; Campi R; Amparore D; De Cillis S; Junlong Z; Guo H; La Bombarda G; Fuschi A; Veccia A; Ditonno F; Marquis A; Barletta F; Leni R; Serni S; Kasivisvanathan V; Antonelli A; Dal Moro F; Rivas JG; van den Bergh RCN; Briganti A; Gandaglia G; Novara G
World J Urol; 2023 Nov; 41(11):3357-3366. PubMed ID: 37755520
[TBL] [Abstract][Full Text] [Related]
2. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
4. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
5. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
[TBL] [Abstract][Full Text] [Related]
7. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
[TBL] [Abstract][Full Text] [Related]
9. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
Hou Y; Jiang KW; Zhang J; Bao ML; Shi HB; Qu JR; Cheng G; Zhang YD
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):727-734. PubMed ID: 35067674
[TBL] [Abstract][Full Text] [Related]
10. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
[TBL] [Abstract][Full Text] [Related]
11. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
13. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for prostate cancer in men with false-negative mpMRI: A retrospective single center cohort study of image quality scores and clinical parameters.
Pausch AM; Ghafoor S; Kluckert J; Rupp NJ; Eberli D; Hötker AM
Eur J Radiol; 2024 Jan; 170():111227. PubMed ID: 38039782
[TBL] [Abstract][Full Text] [Related]
15. Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?
Stabile A; Sorce G; Barletta F; Brembilla G; Mazzone E; Pellegrino F; Cannoletta D; Cirulli GO; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
World J Urol; 2023 Nov; 41(11):3231-3237. PubMed ID: 36943477
[TBL] [Abstract][Full Text] [Related]
16. PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions.
Kwe J; Baunacke M; Boehm K; Platzek I; Thomas C; Borkowetz A
World J Urol; 2024 Feb; 42(1):84. PubMed ID: 38363332
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
[TBL] [Abstract][Full Text] [Related]
18. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.
Barletta F; Mazzone E; Stabile A; Scuderi S; Brembilla G; de Angelis M; Cirulli GO; Cucchiara V; Gandaglia G; Karnes RJ; Roupret M; De Cobelli F; Montorsi F; Briganti A
World J Urol; 2022 Nov; 40(11):2683-2688. PubMed ID: 36149448
[TBL] [Abstract][Full Text] [Related]
19. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
Pellegrino F; Stabile A; Mazzone E; Sorce G; Barletta F; De Angelis M; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2022 Sep; 82(12):1170-1175. PubMed ID: 35538401
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
